These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 39027335)

  • 1. A disproportionality analysis of adverse events caused by GnRHas from the FAERS and JADER databases.
    Zou S; Ouyang M; Zhao Y; Cheng Q; Shi X; Sun M
    Front Pharmacol; 2024; 15():1392914. PubMed ID: 39027335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
    Shu Y; Chen J; Ding Y; Zhang Q
    Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonoprazan-associated
    Ouyang M; Zou S; Cheng Q; Shi X; Zhao Y; Sun M
    Ther Adv Drug Saf; 2024; 15():20420986241260211. PubMed ID: 39091466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
    Nagai J; Ishikawa Y
    PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
    Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases.
    Nomura K; Takahashi K; Hinomura Y; Kawaguchi G; Matsushita Y; Marui H; Anzai T; Hashiguchi M; Mochizuki M
    Drug Des Devel Ther; 2015; 9():3031-41. PubMed ID: 26109846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database.
    Wang X; Chen H; Han S; Li L; Chen H; Yang B
    Front Pharmacol; 2024; 15():1404658. PubMed ID: 39329127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.
    Shu Y; Ding Y; Liu L; Zhang Q
    CNS Neurosci Ther; 2023 Sep; 29(9):2705-2716. PubMed ID: 37032639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
    Ke C; Chen M; Huang Y; Chen Y; Lin C; Huang P
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5253-5264. PubMed ID: 38270617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system.
    Li L; Xu Q; Liu Y; Pang L; Cui Z; Lu Y
    Front Pharmacol; 2024; 15():1403988. PubMed ID: 39114358
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.
    Liang Q; Liao X; Wu H; Huang Y; Liang T; Li H
    Front Pharmacol; 2024; 15():1431562. PubMed ID: 39144633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Chen W; Cai P; Zou W; Fu Z
    Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis.
    Zhang Y; Sun S; Wang Y
    Expert Opin Drug Saf; 2024 Sep; ():1-7. PubMed ID: 39242080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system.
    Zhang Y; Ran L; Liang Y; Zhang Y; An Z
    Front Pharmacol; 2023; 14():1194545. PubMed ID: 37554985
    [No Abstract]   [Full Text] [Related]  

  • 19. Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system.
    Jin Y; Fan M; Zheng X; Zhu S
    Expert Opin Drug Saf; 2024 Aug; ():1-6. PubMed ID: 39167069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database.
    Hu Y; Du Y; Qiu Z; Zhu C; Wang J; Liang T; Liu T; Da M
    Front Pharmacol; 2024; 15():1399998. PubMed ID: 39108741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.